Literature DB >> 26251765

Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Ioannis S Dimopoulos1, Stephanie Chan1, Robert E MacLaren2, Ian M MacDonald1.   

Abstract

INTRODUCTION: Choroideremia is a rare, X-linked disorder recognized by its specific ocular phenotype as a progressive degenerative retinopathy resulting in blindness. New therapeutic approaches, primarily based on genetic mechanisms, have emerged that aim to prevent the progressive vision loss. AREAS COVERED: This article will review the research that has progressed incrementally over the past two decades from mapping to gene discovery, uncovering the presumed mechanisms triggering the retinopathy to preclinical testing of potential therapies. EXPERT OPINION: While still in an evaluative phase, the introduction of gene replacement as a potential therapy has been greeted with great enthusiasm by patients, advocacy groups and the medical community.

Entities:  

Keywords:  REP1; choroideremia; gene therapy; retina

Year:  2015        PMID: 26251765      PMCID: PMC4522943          DOI: 10.1517/21678707.2015.1046434

Source DB:  PubMed          Journal:  Expert Opin Orphan Drugs        ISSN: 2167-8707            Impact factor:   0.694


  89 in total

1.  Choroideremia associated with subretinal neovascular membrane.

Authors:  K Endo; M Yuzawa; N Ohba
Journal:  Acta Ophthalmol Scand       Date:  2000-08

2.  High-resolution adaptive optics retinal imaging of cellular structure in choroideremia.

Authors:  Jessica I W Morgan; Grace Han; Eva Klinman; William M Maguire; Daniel C Chung; Albert M Maguire; Jean Bennett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-04       Impact factor: 4.799

3.  Cloning, mapping and characterization of the human RAB27A gene.

Authors:  T Tolmachova; J S Ramalho; J S Anant; R A Schultz; C M Huxley; M C Seabra
Journal:  Gene       Date:  1999-10-18       Impact factor: 3.688

4.  Macular pigment and lutein supplementation in choroideremia.

Authors:  Jacque L Duncan; Tomas S Aleman; Leigh M Gardner; Elaine De Castro; Daniel A Marks; Jessica M Emmons; Michelle L Bieber; Janet D Steinberg; Jean Bennett; Edwin M Stone; Ian M MacDonald; Artur V Cideciyan; Maureen G Maguire; Samuel G Jacobson
Journal:  Exp Eye Res       Date:  2002-03       Impact factor: 3.467

Review 5.  Gene therapy for choroideremia using an adeno-associated viral (AAV) vector.

Authors:  Alun R Barnard; Markus Groppe; Robert E MacLaren
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-30       Impact factor: 6.915

6.  Choroideremia, sensorineural deafness, and primary ovarian failure in a woman with a balanced X-4 translocation.

Authors:  I J Lorda-Sanchez; A J Ibañez; R J Sanz; M J Trujillo; M E Anabitarte; M E Querejeta; M Rodriguez de Alba; A Gimenez; F Infantes; C Ramos; B Garcia-Sandoval; C Ayuso
Journal:  Ophthalmic Genet       Date:  2000-09       Impact factor: 1.803

7.  Choroideremia: further evidence for assignment of the locus to Xq13-Xq21.

Authors:  M Schwartz; T Rosenberg; E Niebuhr; C Lundsteen; H Sardemann; O Andersen; H M Yang; L U Lamm
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

8.  AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models.

Authors:  Vidyullatha Vasireddy; Jason A Mills; Rajashekhar Gaddameedi; Etiena Basner-Tschakarjan; Monika Kohnke; Aaron D Black; Krill Alexandrov; Shangzhen Zhou; Albert M Maguire; Daniel C Chung; Helen Mac; Lisa Sullivan; Paul Gadue; Jeannette L Bennicelli; Deborah L French; Jean Bennett
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

9.  Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo.

Authors:  Tanya Tolmachova; Oleg E Tolmachov; Alun R Barnard; Samantha R de Silva; Daniel M Lipinski; Nathan J Walker; Robert E Maclaren; Miguel C Seabra
Journal:  J Mol Med (Berl)       Date:  2013-06-12       Impact factor: 4.599

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  13 in total

1.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

Authors:  Tomas S Aleman; Grace Han; Leona W Serrano; Nicole M Fuerst; Emily S Charlson; Denise J Pearson; Daniel C Chung; Anastasia Traband; Wei Pan; Gui-Shuang Ying; Jean Bennett; Albert M Maguire; Jessica I W Morgan
Journal:  Ophthalmology       Date:  2016-12-13       Impact factor: 12.079

2.  CHOROIDEREMIA: Retinal Degeneration With an Unmet Need.

Authors:  Mark E Pennesi; David G Birch; Jacque L Duncan; Jean Bennett; Aniz Girach
Journal:  Retina       Date:  2019-11       Impact factor: 4.256

3.  Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date.

Authors:  Vasiliki Kalatzis; Anne-Françoise Roux; Isabelle Meunier
Journal:  Mol Diagn Ther       Date:  2021-10-18       Impact factor: 4.074

Review 4.  Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy.

Authors:  Carla Sanjurjo-Soriano; Vasiliki Kalatzis
Journal:  Neural Plast       Date:  2018-05-08       Impact factor: 3.599

5.  Whole exome sequencing of a family revealed a novel variant in the CHM gene, c.22delG p.(Glu8Serfs*4), which co-segregated with choroideremia.

Authors:  Handong Dan; Tuo Li; Xinlan Lei; Xin Huang; Yiqiao Xing; Yin Shen
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

6.  Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Patients with Choroideremia.

Authors:  Alexandra S Vitale; Lydia Sauer; Natalie K Modersitzki; Paul S Bernstein
Journal:  Transl Vis Sci Technol       Date:  2020-09-30       Impact factor: 3.283

7.  Bilateral visual acuity decline in males with choroideremia: a pooled, cross-sectional meta-analysis.

Authors:  Duygu Bozkaya; Heng Zou; Cindy Lu; Nicole W Tsao; Byron L Lam
Journal:  BMC Ophthalmol       Date:  2022-01-16       Impact factor: 2.209

Review 8.  The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease.

Authors:  Luis A Martinez Velazquez; Brian G Ballios
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

9.  A Comprehensive Analysis of Choroideremia: From Genetic Characterization to Clinical Practice.

Authors:  Rocio Sanchez-Alcudia; Maria Garcia-Hoyos; Miguel Angel Lopez-Martinez; Noelia Sanchez-Bolivar; Olga Zurita; Ascension Gimenez; Cristina Villaverde; Luciana Rodrigues-Jacy da Silva; Marta Corton; Raquel Perez-Carro; Simona Torriano; Vasiliki Kalatzis; Carlo Rivolta; Almudena Avila-Fernandez; Isabel Lorda; Maria J Trujillo-Tiebas; Blanca Garcia-Sandoval; Maria Isabel Lopez-Molina; Fiona Blanco-Kelly; Rosa Riveiro-Alvarez; Carmen Ayuso
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

10.  Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles.

Authors:  Carla Sanjurjo-Soriano; Nejla Erkilic; David Baux; Daria Mamaeva; Christian P Hamel; Isabelle Meunier; Anne-Françoise Roux; Vasiliki Kalatzis
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-27       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.